A2 Bio publishes key preclinical findings demonstrating potential of its highly selective Tmod™ cell therapy platform to revolutionize the treatment of solid tumors in select patients
/PRNewswire/ -- A2 Biotherapeutics, Inc. ("A2 Bio''), a biotechnology company focused on the treatment of solid tumors, announced today that key preclinical...